Allstate Corp Boosts Position in IDEXX Laboratories, Inc. $IDXX

Allstate Corp increased its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 102.7% in the 4th quarter, Holdings Channel.com reports. The firm owned 5,952 shares of the company’s stock after acquiring an additional 3,015 shares during the quarter. Allstate Corp’s holdings in IDEXX Laboratories were worth $4,027,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in IDXX. Beacon Investment Advisory Services Inc. increased its holdings in shares of IDEXX Laboratories by 11.9% in the fourth quarter. Beacon Investment Advisory Services Inc. now owns 62,951 shares of the company’s stock valued at $42,588,000 after purchasing an additional 6,710 shares during the period. Nordea Investment Management AB increased its holdings in shares of IDEXX Laboratories by 114.1% in the fourth quarter. Nordea Investment Management AB now owns 16,597 shares of the company’s stock valued at $11,283,000 after purchasing an additional 8,845 shares during the period. New York State Common Retirement Fund increased its holdings in shares of IDEXX Laboratories by 6.8% in the third quarter. New York State Common Retirement Fund now owns 60,225 shares of the company’s stock valued at $38,477,000 after purchasing an additional 3,820 shares during the period. Mediolanum International Funds Ltd increased its holdings in shares of IDEXX Laboratories by 14.5% in the third quarter. Mediolanum International Funds Ltd now owns 38,761 shares of the company’s stock valued at $24,441,000 after purchasing an additional 4,909 shares during the period. Finally, Procyon Advisors LLC acquired a new position in IDEXX Laboratories during the fourth quarter worth $1,966,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

Insiders Place Their Bets

In related news, EVP Nimrata Hunt sold 1,758 shares of the stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $634.57, for a total transaction of $1,115,574.06. Following the transaction, the executive vice president directly owned 18,141 shares in the company, valued at approximately $11,511,734.37. This represents a 8.83% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Company insiders own 0.79% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently weighed in on the company. UBS Group dropped their price objective on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a report on Tuesday, April 28th. Citigroup assumed coverage on IDEXX Laboratories in a report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price objective on the stock. BTIG Research dropped their price objective on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating on the stock in a report on Tuesday, February 3rd. Stifel Nicolaus dropped their price objective on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a report on Tuesday, March 31st. Finally, Wall Street Zen lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Seven investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and a consensus target price of $751.00.

IDEXX Laboratories Stock Down 1.1%

Shares of NASDAQ:IDXX opened at $550.99 on Thursday. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19. IDEXX Laboratories, Inc. has a 52-week low of $504.56 and a 52-week high of $769.98. The stock’s fifty day simple moving average is $565.23 and its 200-day simple moving average is $638.69. The company has a market capitalization of $43.46 billion, a P/E ratio of 40.57, a P/E/G ratio of 3.24 and a beta of 1.58.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The business had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.12 billion. During the same period in the prior year, the business earned $2.91 earnings per share. The business’s revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, equities research analysts forecast that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.